Clinical Trials · NCT00082381
Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 551
- Start date
- Jun 2003
- Locations
- 91 sites, 13 countries
- Primary endpoint
- Change in Glycosylated Hemoglobin (HbA1c)